Resources
5 Results (showing 1 - 5)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 9/4/2020 (updated 3/29/2024)
Like all professions, the addictions treatment field is faced with the challenges of employee substance use and abuse and their impact on retention of quality staff. Because the addictions field employees a disproportionate number of individuals – by recent estimates close to half of the treatment workforce – in recovery, the field faces particular retention challenges. This toolkit provides meaningful and practical guidance to the problem of substance misuse among addictions professionals.
Posted 12/3/2019 (updated 3/28/2024)
The report reviews the current evidence-base for the Collaborative Care Model, essential implementation elements with detailed examples, lessons learned by those who have implemented the model, and recommendations for how to advance its use to better meet the whole health needs people with mental health conditions.
Posted 12/3/2019 (updated 3/28/2024)
The National Council for Behavioral Health, through the National Center of Excellence for Integrated Health Solutions (CIHS) grant award from SAMHSA, is the home of the newest evidence-based resources, tools and support for organizations working to integrate primary and behavioral health care.
Posted 7/28/2020 (updated 3/28/2024)
Brandeis University’s Institute for Behavioral Health Opioid Policy Research Collaborative launched the Brandeis Opioid Resource Connector (BORC) website, a comprehensive online resource for communities and local leaders addressing the opioid crisis.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.